Catapult Award supports researchers conducting Phase 1 and Phase 2 pediatric cancer trials, moving promising laboratory findings into patient testing to advance better, less-toxic treatments for children.
Funder: CureSearch for Children's Cancer
Due Dates (Anticipated): October 2027 (LOI) | January 2028 (Full application)
Funding Amounts: $500,000–$2.5 million; awards provide funding over three years
Summary: Supports Phase 1 and Phase 2 pediatric cancer clinical trials advancing promising new treatments from laboratory research into patient testing.
Key Information: Projects are expected to begin patient enrollment within one year of receiving funding.
CureSearch for Children's Cancer’s Catapult Award supports Phase 1 and Phase 2 clinical trials of new treatment approaches for children with cancer. The program funds the transition from promising laboratory research to patient testing, where studies evaluate safety, determine dosing, and examine early signs of benefit before a treatment can become part of routine care.
The award focuses on novel, innovative, less-toxic treatments and provides substantial, multiyear support for projects ready to enter clinical testing. Within CureSearch’s broader research funding strategy, Catapult addresses early clinical development, helping promising science advance toward better, safer treatments for children. Supported approaches include cellular immunotherapies, RNA-nanoparticle vaccines, and therapies targeting vulnerabilities in pediatric brain tumors.